» Articles » PMID: 32944046

Matrix Metalloproteinase-9 (MMP-9) Expression in Non-Small Cell Lung Carcinoma and Its Association with Clinicopathologic Factors

Overview
Journal Iran J Pathol
Date 2020 Sep 18
PMID 32944046
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Objective: Matrix metalloproteinases-9 (MMP-9) is one of the most important enzymes to breakdown extracellular matrix which plays a major role in tumor invasion and metastasis. This study aimed to determine tumor MMP-9 expression in non-small-cell lung carcinoma (NSCLC) and whether it is associated with histopathologic factors and has prognostic value to affect overall survival (OS).

Methods: The specimens of 92 patients with NSCLC diagnosis were included. Tumor sections were stained by immunohistochemistry method. Using scores for the percentage of cells positively stained and the intensity of staining, MMP-9 expression total score was classified as low-score (scores of 0 to 2), moderate-score (scores of 3 to 5), or high-score (scores of 6 or 7). OS was defined as the time interval since the diagnosis of NSCLC to the status at the last follow-up (dead or alive). The follow up period was up to 70 months.

Results: About 74% of undifferentiated specimens (grade III tumors) showed high scores for MMP-9 expression which was significantly higher than moderately differentiated tumors (25% had high scores for MMP-9 expression) and well differentiated ones which did not have high scores (<0.001). A total of 74 patients (80.4%) died during the follow-up period. Of this, 36% had high scores for MMP-9 expression. In contrast, none of the patients who were alive at the last follow-up had high scores for MMP-9 expression (<0.001). Median OS was significantly lower in high score group (6 months) compared to moderate score (9 months) and high score group (15 months) (<0.001).

Conclusion: MMP-9 expression may serve as a significant prognostic factor for mortality and overall survival in NSCLC. Undifferentiated tumors significantly express higher MMP-9 immunohistochemically.

Citing Articles

Early Effects of Modern Radiotherapy for Lung Cancer on Endothelial Damage and Myocardial Fibrosis: A Prospective Single-Center Study.

Slawinski G, Hawryszko M, Lasocka-Koriat Z, Romanowska A, Myszczynski K, Wrona A Int J Mol Sci. 2024; 25(12).

PMID: 38928407 PMC: 11204135. DOI: 10.3390/ijms25126705.


The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance.

Alhaddad L, Osipov A, Leonov S Int J Mol Sci. 2022; 23(21).

PMID: 36362359 PMC: 9656305. DOI: 10.3390/ijms232113577.


Up-regulation of matrix metalloproteinase-9 in primary bone tumors and its association with tumor aggressiveness.

Vaezi M, Eghtedari A, Safizadeh B, Ghasempour G, Salimi V, Nourbakhsh M Mol Biol Rep. 2022; 49(10):9409-9427.

PMID: 36002655 DOI: 10.1007/s11033-022-07798-z.


Effects and mechanism of miR-133a on invasion and migration of lung cancer cells.

Yu B, Pang J, You J Am J Transl Res. 2022; 14(2):728-739.

PMID: 35273681 PMC: 8902573.

References
1.
Vandooren J, Van den Steen P, Opdenakker G . Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013; 48(3):222-72. DOI: 10.3109/10409238.2013.770819. View

2.
Wen Y, Li L . Correlation between matrix metalloproteinase-9 and vascular endothelial growth factor expression in lung adenocarcinoma. Genet Mol Res. 2016; 14(4):19342-8. DOI: 10.4238/2015.December.29.44. View

3.
Cooke D, Nguyen D, Yang Y, Chen S, Yu C, Calhoun R . Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg. 2010; 90(3):943-8. DOI: 10.1016/j.athoracsur.2010.05.025. View

4.
Cox G, Jones J, OByrne K . Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000; 6(6):2349-55. View

5.
Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C . Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol. 2010; 5(9):1354-60. DOI: 10.1097/JTO.0b013e3181e77a78. View